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The performance of lab tests (LT) and blood testing devices (BTD) to monitor glycemia vs. glycated 
hemoglobin A1c (A1c) were compared. In addition, the performance of blood glucose, total cholesterol 
(TC) and triacylglycerol measured by LT and BDT were compared. All parameters were measured based 
on the same blood samples from overnight fasted type 2 diabetic patients (T2DP). Linear regression 
analysis was used for all comparisons. The results showed that A1c correlated better with LT-glucose 
(r = 0.58) than BTD-glucose (r = 0.42). Moreover, LT vs. BTD showed r values of 0.90, 0.82 and 0.92 
for glucose, TC and triacylglycerol, respectively. It was concluded that the performance of LT-glucose 
was better than BDT-glucose. Moreover, since triacylycerol and TC measured by BTD correlated better 
with LT compared to BDT-glucose vs. LT-glucose, the inclusion of BTD-TC and BTD-triacylglycerol 
for detecting and monitoring hyperlipidemia in T2DP should be considered. 
Uniterms: Laboratory tests. Glycated hemoglobin. Glycemia. Total cholesterol. Triacylglycerol. Type 
2 diabetes.
Comparou-se a performance de avaliação da glicemia através de dosagens laboratoriais (DL) ou 
dispositivo para teste de sangue capilar (DTSC) vs. hemoglobina glicada A1c (A1c). Comparou-se 
ainda a performance de avaliação da glicemia, colesterol total (CT) e triacilglicerol (DL vs. DTSC). 
Avaliou-se estes parametros a partir das mesmas amostras de sangue coletadas em pacientes diabéticos 
tipo 2 (PDT2) em jejum noturno, sendo as comparações realizadas através de análise de regressão 
linear. A A1c correlacionou-se melhor com a glicemia-DL (r = 0,58) em relação a glicemia-DTSC 
(r = 0,42). Comparou-se DL vs. DTSC obtendo se r = 0,90, 0,82 e 0,92 para glicemia, CT e triacilglicerol, 
respectivamente. Concluiu-se que houve melhor performance da glicose-DL em relação a glicose-DTSC. 
Além disso, considerando que o triacilglicerol e TC avaliado através de DTSC correlaciona-se melhor 
com DL em comparação a DTSC-glicose vs. DL-glicose, a inclusão de DTSC-TC e DTSC-triacilglicerol 
visando detectar e monitorar hyperlipidemia in PDT2 deve ser considerada. 
Unitermos: Exames laboratoriais. Hemoglobina glicada. Glicemia. Colesterol total. Triacilglicerol. 
Diabetes tipo 2.
INTRODUCTION
Glycemic control is fundamental in the management 
of type 2 diabetes. The United Kingdom Prospective Dia-
betes Study (UKPDS), a prospective, randomized, control-
led trial of intensive versus standard glycemic control in 
type 2 diabetic patients, showed definitively that improved 
glycemic control is associated with significantly decreased 
rates of diabetic complications (UK Prospective diabetes 
study group (1998).
Moreover, epidemiological analyses of the UKPDS 
demonstrated a curvilinear relationship between glycated 
hemoglobin A1c and diabetic complications, suggesting 
that the majority of complications could be prevented by 
the implementation of good glycemic control (Stratton et 
A. Zubioli, M.R. Batista, T.F. Stefanello, M.A. Carrara, R.B. Bazotte616
al., 2000). This study also suggested that further lowering 
of glycated hemoglobin A1c from 7 to 6% was associated 
with significant reduction of diabetic complications. In 
agreement, the American Diabetes Association sugges-
ted glycated hemoglobin A1c of less than7% to prevent 
chronic complications (American Diabetes Association, 
2010).
However, in spite the fact that glycated hemoglo-
bin A1c is considered the cornerstone of clinical mana-
gement of diabetes, (American Diabetes Association, 
2010) fasting glycemia is the most widely used lab test 
to evaluate the glycemic status of people with diabetes 
(Al-Lawati, Al-Lawati, 2007; Correr et al., 2009; Silva 
et al., 2004). 
Furthermore, in recent years a clear tendency for 
evaluating blood glucose, total cholesterol and triacyl-
glycerol with blood testing devices has emerged (Laguna 
et al., 2009; Nathan et al., 2008; Cassani et al., 2009; Pon-
gwecharak, Treeranurat, 2010). However, the performance 
of these methods in comparison with classical lab tests is 
not yet well established. 
In the present investigation, the performance of 
blood glucose measurements from lab tests and blood 
testing devices for glycated hemoglobin A1c levels was 
compared. Moreover, the performance of lab tests and 
blood testing devices was also compared for glucose, total 
cholesterol and triacylglycerol measurements.
PATIENTS AND METHODS
Written consent to participate in this investigation 
was obtained from each patient and the study was appro-
ved by the Ethics Committee of the State University of 
Maringá (COPEP - CAAE 0133-06).
Exclusion criteria were pregnancy, gestational dia-
betes, type 1 diabetes and other specific types of diabetes. 
Eligibility criteria were: age over 30 years, confirmed 
diagnosis of type 2 diabetes and use of at least one pres-
cribed anti-diabetic drug.
The patients, recruited from a pharmacy school, 
were interviewed and information on medical history, 
socio-demographic characteristics, pharmacotherapeutic 
profile and lifestyle were collected. After the interview, 
blood pressure (BP) and body mass index (BMI) were 
evaluated. BP (mmHg) was measured as described else-
where (Ferri et al., 2006).
Immediately after the interview the patients received 
instructions for blood collection at a laboratory accredited 
by the Brazilian Society of Clinical Analysis. 
Venous blood was collected from overnight fasted 
patients for analysis of glucose, total cholesterol and 
triacylglycerol by a blood testing device (BTD) and lab 
tests (LT). In addition, glycated hemoglobin A1c was 
measured. All analyses were done from the same blood 
sample.
Immediately after blood collection, part of the fresh 
blood was immediately used to measure glycated hemo-
globin A1c (Metus et al., 1999), glucose, total cholesterol 
and triacylglycerol by BTD (Accutrend GCT® - Roche 
Company). The normal values of glycated hemoglobin 
A1c, glucose, total cholesterol and triacylglycerol were 
< 7%, 70-130 mg/dL, < 200 mg/dL and < 200 mg/dL, 
respectively.
Moreover, part of the blood was transferred to a 
tube containing sodium fluoride/EDTA, which was imme-
diately centrifuged and the plasma separated to measure 
glucose (Bergmeyer, Bernt, 1974), total cholesterol (Allain 
et al., 1974) and triacylglycerol (Bucolo, David, 1973) by 
LT. The normal values of blood glucose, total cholesterol 
and triacylglycerol were < 100 mg/dL, < 200 mg/dL, and 
< 150 mg/dL, respectively. These values were based in the 
position statement of the Clinical Practice Recommenda-
tion of the American Diabetes Association (2010).
Linear regression analysis using GraphPad Prism 
(version 5) was done to investigate the relationship be-
tween glycated hemoglobin A1c vs. glucose (LT), A1c vs. 
glucose (BTD), glucose (LT vs. BTD), total cholesterol 
(LT vs. BTD) and triacylglycerol (LT vs. BTD).
Some results were expressed as percentage (%) and 
others as mean ± standard deviation (SD).
RESULTS
A total of 32 volunteers, 16 (50%) men and 16 (50%) 
women, were assessed. The values for all biochemical 
parameters did not differ between men and women (data 
not shown). 
Among these patients, whose mean age was 57.8  ± 
7.3 years ranging from 48 to 74 years, the time of  diag-
nosis was 12.0  ± 9.0 years, ranging from 1 to 37 years.
Most patients had one or more comorbidities asso-
ciated with diabetes, with a prevalence of hypertension 
(93.8%) and overweight or obesity (68.8%).
The value of glycated hemoglobin A1c, glucose 
(LT), glucose (BTD), total cholesterol (LT), total choleste-
rol (BTD), triacylglycerol (LT) and triacylglycerol (BTD) 
were 9.2 ± 2.3%,  176.5 ± 56.3 mg/dL, 129.2 ± 44.2 mg/dL, 
181.1 ± 36.9 mg/dL, 182.2 ± 21.8 mg/dL, 147.5 ± 88.0 mg/dL 
and 194.7 ± 90.0 mg/dL, respectively.
The number (%) of patients with altered values for 
glycated hemoglobin A1c, glucose (LT), glucose (BTD), 
total cholesterol (LT), total cholesterol (BTD), triacyl-
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glycerol (LT) and triacylglycerol (BTD) were 25 (78.1%), 
24 (75.0%), 14 (43.8%), 9 (32%), 4 (14.3%), 10 (33.3%) 
and 13 (41.9%), respectively (Table I).
As can be seen in Figure 1A and 1B, glycated 
hemoglobin A1c correlated better with glucose measu-
red by LT (r = 0.58) than BTD (r = 0.42). On the other 
hand, the comparison of LT and BTD show r values of 
0.90, 0.82, 0.92 and glucose (Figure 2A), total cho-
lesterol (Figure 2B) and triacylglycerol (Figure 2C), 
respectively. 
TABLE I - Individual and mean (M) ± standard deviation (SD) of glycated hemoglobin A1c (A1c), blood, glucose (GLU), total 
cholesterol (TC) and triacylglycerol (TG). GLU, TC and TG were measured by Lab test (LT) and blood testing device (BTD). A1c 
was expressed as % and all other parameters were expressed as mg/dL. Blood was collected from overnight fasted type 2 diabetic 
patients. nd: not determined
Patient A1c GLU – LT GLU-BTD TC – LT TC-BTD TG – LT TG – BTD
1 8.4 156 88 166 150 192 229
2 8.2 192 158 237 193 224 267
3 9.9 188 117 107 167 88 143
4 9.5 180 98 172 193 322 246
5 10.3 169 103 170 174 93 146
6 12.8 229 158 202 196 202 255
7 7.5 168 144 202 190 130 192
8 9.6 264 196 172 180 206 292
9 9.6 196 169 142 169 192 193
10 11.6 252 179 210 200 95 138
11 12.4 266 216 218 223 122 177
12 8.7 229 146 nd nd nd 101
13 10.6 137 77 182 168 103 156
14 6.4 113 94 nd nd 127 203
15 7.2 164 110 nd nd 110 208
16 6.4 103 83 116 168 68 120
17 7.5 121 101 180 171 46 89
18 6.8 92 73 171 165 108 97
19 11.5 219 175 175 180 471 548
20 11.6 301 234 174 169 132 198
21 7.4 126 130 151 157 64 101
22 9.1 212 171 152 165 135 198
23 9.4 184 145 198 175 160 221
24 7.0 173 134 181 175 115 171
25 6.9 148 97 196 185 88 138
26 8.7 51 53 202 200 37 88
27 7.2 156 107 207 199 119 183
28 14.1 173 87 286 250 nd nd
29 13.9 155 114 132 160 91 134
30 6.8 126 91 nd nd 143 213
31 12.2 258 176 215 213 192 269
32 6.3 148 111 157 168 250 322
M 9.2 176.5 129.2 181.1 182.2 147.5 194.7
SD 2.3 56.3 44.2 36.9 21.8 88.0 92.0
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DISCUSSION
Type 2 diabetes is now a major public health pro-
blem in Brazil. The estimated number of 5.2 million suffe-
rers in 2000 is expected to double by the year 2030 (Wild 
et al., 2004). However, glycemic control is lower than 
50% (Gomes et al., 2006; Assunção, Santos, Valle, 2005), 
which inevitably contributes to the increasing occurrence 
of chronic complications in type 2 diabetic patients.
Furthermore, type 2 diabetes is normally asymp-
tomatic, but if the disease is not adequately treated a 
range of chronic complications can result in reduced 
quality of life and premature death (Assunção, Santos, 
Valle, 2005).
Therefore, monitoring the treatment of type 2 dia-
betes has important implications for individual health and 
public health policy and for this purpose fasting glycemia 
is the most commonly used exam (Silva, Bazotte, 2010; 
Pimentel et al., 2010).   Moreover, considering the high 
risk of cardiovascular disease, the control of blood lipid 
profile must be considered (Colagiuri, 2010).
Our results showed that the majority of the patients 
did not exhibit suitable control of glycemia and lipid pro-
file (Table I). These results are in line with the findings 
of several other studies, in which the majority of type 2 
diabetic patients exhibited poor blood glucose and lipid 
control (Kemp et al., 2005; Saydah, Fradkin, Cowie, 2004; 
McFarlane et al., 2002; Grant, Buse, Meigs, 2005; Silva, 
Bazotte, 2010).
Linear regression analysis to investigate the rela-
tionship between glycated hemoglobin A1c vs. fasting 
glycemia (LT and BTD) revealed that glycated hemoglo-
bin A1c correlated better with LT than with BTD (Figure 
1A, B). Furthermore, in the case of patients 1,4,13,26 and 
28 (Table I), fasting glycemia obtained by BTD, i.e., ≤ 
100 mg/dL, could yield misleading information of good 
glycemic control since results contrasted with the elevated 
values of glycated hemoglobin A1c. For LT, this problem 
is limited to patient 26 (Table I). Therefore, in spite of the 
fact that glycemia measured by BTD has become faster 
and more accurate over the past 3 decades and now allows 
FIGURE 1 - Relationship between glycated hemoglobin A1c 
(HbA1c) and fasting glycemia measured by Lab test (1A) and 
blood testing device (BTD) (1B). Number of patients: 32.
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FIGURE 2 - Relationship between lab test and blood testing 
device (BTD) for glycemia (2A), total cholesterol (2B) and 
triacylglycerol (2C). Number of patients: 32.
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for better glycemic control by diabetics than in the past, 
this test is no substitute for fasting glycemia values obtai-
ned by lab tests.
There is consensus on continuous monitoring of 
lipid profile in type 2 diabetes. This question acquires 
greater relevance considering that diabetes is a significant 
cardiovascular risk and given that blood lipid targets are 
not attained by the majority of type 2 diabetic patients 
(Gomes et al., 2006; Grant, Buse, Meigs, 2005; Silva, 
Bazotte, 2010). In this context, our results showed that, in 
spite of the fact that BTD for measuring total cholesterol 
and triacylglycerol were introduced into clinical practice 
later than glycemia, they show good correlation with 
laboratory results. In the specific case of triacylglycerol, 
the r value (r = 0.92) for comparison of BTD vs. LT was 
higher than that obtained for glucose (r = 0.90).
CONCLUSION
Congruent with the well-established role of BTD in 
the detection and self-monitoring of glycemia, the Brazi-
lian Government approved RDC 44/ANVISA (Resolução 
da Diretoria Colegiada, 2009) in which capillary glycemia 
was established as a pharmaceutical service care for diabe-
tes screening and glucose monitoring. However, conside-
ring that glycated hemoglobin A1c correlated better with 
LT than BTD, device tests are no substitute for the fasting 
glycemia values obtained by lab tests. Finally, since BTD-
TC and BTD-triacylglycerol showed good correlation with 
LT, the inclusion of BTD-TC and BTD-triacylglycerol in 
the detection and monitoring of hyperlipidemia in T2DP 
should be considered.
Finally, any analysis of the results must consider the 
limited number of patients investigated, i.e., 32 volunteers. 
However, this limitation was overcome, partly at least, by 
the fact that all biochemical parameters were evaluated 
based on the same blood sample. This experimental ap-
proach, in which each patient served as their own control, 
rules out the interference of several factors such as age, 
duration of diabetes, gender, BMI and variability owing to 
blood collection on different days. However, future studies 
involving a higher number of patients are necessary to 
confirm the conclusions of this study.
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